A comprehensive review published in Blood Research synthesizes the rapidly evolving landscape of treatment strategies for acute myeloid leukemia (AML), highlighting a paradigm shift from uniform cytotoxic chemotherapy toward precision-based approaches guided by molecular profiling and measurable residual disease (MRD) assessment. The study, authored by Shailesh Simkhada, Utsav Joshi, and Prajwal Dhakal, examines how the integration of genomics has enabled genotype-directed therapy, accelerating the incorporation of targeted agents into both intensive and lower-intensity treatment regimens. This synthesis focuses on pivotal clinical data and translational principles informing emerging targeted, immune-based, and cellular strategies, with a particular emphasis on remission depth, MRD-driven decision-making, and relapse prevention in a molecularly diverse hematologic malignancy.
Acute myeloid leukemia is characterized by the clonal expansion of immature myeloid precursors, resulting in ineffective hematopoiesis and bone marrow failure. Clinical outcomes vary widely and are determined by patient fitness, disease biology, and the depth of response, making risk-adapted management essential. Contemporary risk stratification relies on the European LeukemiaNet (ELN) 2022 and 2024 frameworks, which integrate cytogenetic and molecular features to categorize patients into favorable-, intermediate-, and adverse-risk groups. For decades, therapy has relied predominantly on cytotoxic chemotherapy with limited personalization, but the routine implementation of molecular studies has shifted clinical practice toward genomics-informed care by identifying actionable alterations and enabling biologically rational treatment selection.
FLT3 mutations are present in approximately 30% of newly diagnosed AML cases, most commonly as internal tandem duplications (FLT3-ITD) and less frequently as tyrosine kinase domain (TKD) mutations. FLT3-ITD activates downstream proliferative and survival pathways, associated with leukocytosis, increased relapse risk, and inferior survival. Type I inhibitors, such as midostaurin, gilteritinib, and crenolanib, inhibit both FLT3-ITD and a broad range of TKD mutations, whereas type II inhibitors, such as quizartinib and sorafenib, are primarily active against FLT3-ITD. In the phase III QuANTUM-First trial, quizartinib improved overall survival in newly diagnosed patients with FLT3-ITD AML when added to intensive induction and consolidation therapy. In relapsed or refractory disease, gilteritinib remains a standard targeted option based on the phase III ADMIRAL trial, which showed improved overall survival and higher complete remission rates compared to salvage chemotherapy.
Post-transplant maintenance remains a critical area of FLT3 inhibitor development. Sorafenib maintenance after allogeneic hematopoietic cell transplantation (allo-HCT) improved relapse-free survival in FLT3-ITD AML in randomized studies. In the phase III MORPHO trial, gilteritinib maintenance did not significantly improve relapse-free survival in the overall intention-to-treat population; however, benefit was observed among patients with detectable FLT3-ITD MRD before or after transplantation. This finding supports an MRD-adapted approach to post-HCT FLT3 inhibition, highlighting the increasing importance of molecular monitoring in selecting patients who are most likely to benefit from maintenance therapy. Next-generation and combination approaches are becoming increasingly relevant, particularly in older or intensive therapy-ineligible patients, with early-phase studies showing encouraging activity for crenolanib or gilteritinib combined with intensive chemotherapy.
Neomorphic IDH1/2 mutations in AML confer gain-of-function activity that converts alpha-ketoglutarate to R-2-hydroxyglutarate, disrupting epigenetic control and enforcing a hypermethylated state. IDH inhibitors suppress the mutant enzymes, reduce 2-HG levels, restore dioxygenase activity, and promote blast differentiation. For newly diagnosed patients with IDH1-mutated AML ineligible for intensive chemotherapy, azacitidine plus ivosidenib is an established frontline lower-intensity treatment option. In the phase III AGILE trial, this combination improved long-term survival compared to azacitidine alone, with a median overall survival of 29.3 versus 7.9 months. The combination also improved complete remission rates, transfusion independence rates, and molecular MRD negativity after a median follow-up of 28.6 months. Ivosidenib monotherapy has also demonstrated clinically meaningful activity in both newly diagnosed and relapsed or refractory settings, providing a treatment option when combination regimens are not feasible.
Enasidenib, an oral selective IDH2 inhibitor, has established single-agent and combination activity in IDH2-mutated AML. In the randomized phase III IDHENTIFY trial, enasidenib did not significantly improve overall survival compared with conventional care in patients 60 years or older with relapsed or refractory IDH2-mutated AML. However, significant improvements were reported in key secondary endpoints, including event-free survival, time to treatment failure, overall response rate, and RBC transfusion independence. In newly diagnosed patients ineligible for intensive therapy, a randomized phase Ib/II trial demonstrated that azacitidine plus enasidenib improved responses compared with azacitidine alone. These data support enasidenib as a rational standard option for relapsed or refractory IDH2-mutated AML, particularly when hematologic recovery and transfusion endpoints are prioritized. IDH inhibitors require monitoring for differentiation syndromes, with ivosidenib potentially prolonging QTc and enasidenib causing indirect hyperbilirubinemia.
Venetoclax, a highly selective BCL-2 inhibitor, has become a cornerstone for older or unfit patients with AML. In the phase III VIALE-A study, the combination of azacitidine and venetoclax improved median overall survival from 9.6 to 14.7 months compared with azacitidine alone in patients with newly diagnosed AML who were ineligible for intensive chemotherapy. The combination also achieved higher MRD-negative rates and more durable transfusion independence. The phase III VIALE-C trial of low-dose cytarabine plus venetoclax reported increased complete remission rates and numerically improved median overall survival compared with low-dose cytarabine alone. Although the primary overall survival endpoint was not met at the planned analysis, the benefit became statistically significant with additional follow-up. Venetoclax-based regimens are being optimized through response-adapted dosing and careful partner selection to mitigate cytopenias while deepening remission, with the major clinical limitation being prolonged myelosuppression and infection risk.
Menin inhibitors represent a major therapeutic advance for KMT2A-rearranged and NPM1-mutated AML. Menin functions as a critical scaffold for KMT2A-associated transcriptional complexes that maintain aberrant HOX/MEIS1 programs and leukemic self-renewal. Revumenib, the most extensively studied oral menin inhibitor, is FDA-approved for relapsed or refractory acute leukemia with KMT2A rearrangements and for relapsed or refractory NPM1-mutated AML. In the phase I/II AUGMENT-101 study, revumenib demonstrated meaningful single-agent activity in heavily pretreated patients, with overall response rates of 60% in KMT2A-rearranged AML and 45-50% in NPM1-mutated AML. Ziftomenib, another oral menin inhibitor, is FDA-approved for adults with relapsed or refractory NPM1-mutated AML based on the KOMET-001 trial, where the pivotal dose achieved complete remission rates of 20-25% in a heavily pretreated population. Both agents share on-target differentiation syndrome risk, with QTc prolongation being a key safety consideration for revumenib.
Immune and cellular therapies are under investigation to address residual disease and relapse, although durable, practice-changing benefits outside select settings remain limited to date. Gemtuzumab ozogamicin (GO), an established anti-CD33 antibody-drug conjugate, has shown the clearest benefit in selected favorable-risk AML, particularly core-binding factor AML, when added to intensive chemotherapy. In the phase III ALFA-0701 trial, fractionated GO added to standard induction improved event-free survival and relapse-free survival. CD47/SIRPalpha checkpoint blockade with magrolimab has not improved survival in previously untreated TP53-mutated AML or in untreated AML ineligible for intensive therapy, with studies stopped early for futility and excess mortality. Newer CD47-axis agents are being re-engineered using Fc-silent antibodies and SIRPalpha fusion formats to improve therapeutic index. PD-1 and PD-L1 inhibitors remain investigational in AML, with randomized and post-remission studies not demonstrating clear practice-changing benefit.
CD123-directed agents offer another avenue for targeted therapy. Tagraxofusp, a CD123-directed cytotoxin, is established in blastic plasmacytoid dendritic cell neoplasms, but its role in AML remains unclear. Pivekimab sunirine, a CD123-targeting humanized antibody drug conjugate, achieved an overall response rate of approximately 21% in a first-in-human phase I/II trial in relapsed or refractory AML. Early phase Ib/II studies of pivekimab sunirine with azacitidine, with or without venetoclax, showed encouraging activity in CD123-positive AML, with deep remissions among responders. Vibecotamab, a bispecific antibody targeting both CD123 and CD3, redirected cytotoxic T-cells to CD123-expressing blasts, with responses observed in approximately 9% of patients in a phase I study. Cytokine release syndrome was observed in approximately 59% of patients treated with vibecotamab, predominantly at grade 2 or lower.
Chimeric antigen receptor T-cell (CAR-T) and CAR natural killer (CAR-NK) cell therapies target AML surface antigens in an HLA-independent manner. CAR-T approaches in AML remain early-phase, limited by antigen overlap with normal myeloid progenitors, disease heterogeneity, and impaired persistence in an immunosuppressive marrow niche. In a first-in-human phase I study in relapsed or refractory AML, complete remission or complete remission with incomplete hematologic recovery was achieved in 70% of patients targeting CLL-1, but all patients had severe pancytopenia. CAR-NK platforms offer potential advantages, including lower rates of severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and the feasibility of allogeneic, off-the-shelf manufacturing. In a phase I study of CD33 CAR NK cells, MRD-negative complete remission was achieved in 6 of 10 patients by day 28. Bispecific T-cell engagers and dual-affinity re-targeting antibodies simultaneously bind CD3 on T cells and a myeloid antigen on AML blasts, inducing immune synapse formation and HLA-independent T-cell cytotoxicity.
The review emphasizes that treatment selection is increasingly guided by patient fitness, ELN risk, actionable genomic alterations, MRD status, and transplantation eligibility. In fit patients, intensive chemotherapy remains the backbone treatment, with FLT3 inhibitors for FLT3-mutated AML and gemtuzumab ozogamicin for selected favorable-risk disease. In older or intensive therapy-ineligible patients, lower-intensity options include azacitidine-venetoclax for many patients and azacitidine-ivosidenib for IDH1-mutated AML. In relapsed or refractory AML, targeted options include gilteritinib for FLT3-mutated disease, IDH inhibitors for IDH1/2-mutated disease, and menin inhibitors for KMT2A-rearranged or NPM1-mutated AML. MRD status and transplant fitness further guide consolidation, allo-HCT, maintenance, and clinical-trial strategies.
Several limitations should be considered when interpreting the emerging AML therapeutic literature summarized in this review. Many novel combinations are supported by early-phase, single-arm, or molecularly selected studies with small sample sizes, heterogeneous prior therapies, variable MRD assays, and limited follow-ups. Cross-trial comparisons are challenging because of differences in patient fitness, ELN risk, transplant eligibility, prior venetoclax or targeted therapy exposure, and response definitions. Deeper remission or higher MRD-negative rates do not always translate into improved survival, as illustrated by several negative randomized trials. Promising investigational strategies should be interpreted cautiously until they are validated in prospective, randomized, or biomarker-directed studies. Future progress will depend on biomarker-enriched trials, standardized MRD endpoints, careful toxicity monitoring, and rational sequencing strategies that balance remission depth with treatment-related morbidity.
Subject of Research: Novel treatment strategies in acute myeloid leukemia
Article Title: Novel treatment strategies in acute myeloid leukemia
Article References: Simkhada, S., Joshi, U., & Dhakal, P. (2026). Novel treatment strategies in acute myeloid leukemia. Blood Research, 61(1), Article 31. https://doi.org/10.1007/s44313-026-00146-1
Image Credits: AI Generated
DOI: 10.1007/s44313-026-00146-1
Keywords: Novel, treatment, strategies, acute, myeloid, leukemia, scientific research
News Source: Ophelia Keating. (November 10, 2026). Review Maps Emerging AML Therapies and Molecular Targets. Scienmag.



